Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarlan cancer treated with cisplatin: Results of a double-blind, randomised trail

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 569-573

  Smyth, J F ^a   Bowman, A ^a   Perren, T ^b   Wilkinson, P ^b   Prescott, R J ^c   Quinn, K J ^d   Tedeschi, M ^e  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e Boekringer Mannheim   (United Kingdom)

Author keywords

Cisplatin; Glutathione; Platinum; Toxicity

Indexed keywords

ANTIDOTE; ANTINEOPLASTIC AGENT; CISPLATIN; GLUTATHIONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIDOTES; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GLUTATHIONE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 0031158107     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008211226339     Document Type: Article

References (17)

1. Cancer Research Campaign Factshects 1.3 & 3.3. 1990 and 1989 respectively.
2. Thigpen JT. HoskinsWj. Cancer of the Ovary. Princeton: BrisiolMyers Squibb 1992.
3. Ozols RF. Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18:222-32.
4. Young RC. Knapp RC. Ferez LA. Cancer of die ovary. In De Vita VT. Meilman S. Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia: Lippincoit Publishers 1984.
5. Lippman SM. Alberts DS. Slyrnen DK et al. Second-look laparolomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer 1988: 61: 2571 7.
6. Harriers FPT. Srakkee JH. Cavalletti E et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544-9.
7. Cavalletti G. Minoia C. Schieppati M et al. Protective effects of glutathione on cispiatin neurotoxicity ir. rats. Exp Neurol (in press).
8. Di Re F. Rohm S. Oriana S et al. Efficacy and safety of high-dose cispiatin in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol 1990: 25: 355-60.
9. Locatedl MC. DAniona A.Vinci M et ai. Cisplatinum (CDDP) icyclophosphamice (CPA) + reduced glutaîhione jGSH) in advanced epithelial ovarian carcinoma. Sixth International Symposium on 'Platinum ar.c other metal co-ordination cor.ipour.cs in cancer chemotherapy'. San Diego, 23-26 January 1991.
10. Aebi S. Asscrata R. Lauterbarg BH. High-dose intravenous giutathion: in nan. Pharmacckineiics and effects on cysteir.(e) in plasma and urine. Bur J Invest 1991: 21: 103-10.
11. Zunino F. Pratesi G. Micheioni A et ai. Protective effect of reduced glutr.tnione against cisplann-indueea renai and systemic toxicity and its influence on the therapeutic activity of the antitumour drug. Chcrn Biol Intern 1989: 70: 89-lOi.
12. Zigmond AS. Snaith RP. The hospital anxiety and depression scale. Acta Psychia;r Scand 1983: 67: 361.
13. De Haes JCJM. van Ostrom MA. Weivaart K. The eM'ect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur .1 Surg Oncol 19S6: 12: 337.
14. Zelen M. The analysis of several 2x2 contingency tabies. Biometrika 1971:58: .29 37.
15. Cochran WG. Some methods for strengthening the common x" tests. Biometrics 1954; 10: 417-454.
16. Armitage P. Test for linear trend in proportions and frequencies. Biometrics 1955: 11: 375 86.
17. Gart J. Point and interval estimation of the common odds ration in the combination cf 2 x 2 tables with fixed marginals. Biometrika 1970: 57: 417 75.